Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

Cancer Research

Volumn 67, Issue 15, 2007, Pages 7450-7457

  Dieli, Francesco ^a   Vermijlen, David ^b,e   Fulfaro, Fabio ^a   Caccamo, Nadia ^a   Meraviglia, Serena ^a   Cicero, Giuseppe ^a   Roberts, Andrew ^b   Buccheri, Simona ^a   D'Asaro, Matilde ^a   Gebbia, Nicola ^a   Salerno, Alfredo ^a   Eberl, Matthias ^c,d   Hayday, Adrian C ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BERN   (Switzerland)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^e UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; DOCETAXEL; GAMMA INTERFERON; GONADORELIN DERIVATIVE; INTERLEUKIN 2; PARACETAMOL; PERFORIN; PROSTATE SPECIFIC ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DETERIORATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; EFFECTOR CELL; FATIGUE; FEASIBILITY STUDY; FLU LIKE SYNDROME; HUMAN; INJECTION SITE ERYTHEMA; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; MEMORY T LYMPHOCYTE; METASTASIS; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; HUMANS; IMIDAZOLES; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; REMISSION INDUCTION; SALVAGE THERAPY; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 34547638252     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0199     Document Type: Article

References (47)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin 2005;55:10-30.
2. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910-4.
3. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23.
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
5. Bhandari MS, Petrylak DP, Hussain M. Clinical trials in metastatic prostate cancer - has there been real progress in the past decade? Eur J Cancer 2005;41:941-53.
6. Diaz M, Patterson SG. Management of androgenin-dependent prostate cancer. Cancer Control 2004;11:364-73.
7. McNeel DG, Malkovsky M. Immune-based therapies for prostate cancer. Immunol Lett 2005;96:3-9.
8. Ragde H, Cavanagh WA, Tjoa BA. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 2004;172:2532-8.
9. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006;90:1-50.
10. Gattinoni L, Powell DJ, Jr., Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006;6:383-93.
11. Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by γδ T cells. Science 2001;294:605-9.
12. Belmant C, Decise D, Fournie JJ. Phosphoantigens and aminobisphosphonates: new leads targeting γδ T lymphocytes for cancer immunotherapy. Drug Discov Today 2006;3:17-23.
13. + γδ-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J Urol 2005;173:1552-6.
14. Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human Vγ9Vδ2 γδ T cells in vitro and in SCID mice in vivo. J Immunol 2004;173:6767-76.
15. Kunzmann V, Wilhelm M. Anti-lymphoma effect of γδ T cells. Leuk Lymphoma 2005;46:671-80.
16. Kabelitz D,Wesch D, He W. Perspectives of human γδ T cells in tumor immunology. Cancer Res 2007;67:5-8.
17. Morita CT, Mariuzza R, Brenner MB. Antigen recognition by human γδ T cells: pattern recognition by the adaptive immune system. Springer Semin Immunopathol 2000;22:191-217.
18. Constant P, Davodeau F, Peyrat MA, et al. Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands. Science 1994;264:267-70.
19. Eberl M, Hintz M, Reichenberg A, Kollas AK, Wiesner J, Jomaa H. Microbial isoprenoid biosynthesis and human γδ T cell activation. FEBS Lett 2003;544:4-10.
20. Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature 1995;375:155-8.
21. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-8.
22. Scotet E, Martinez LO, Grant E, et al. Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 2005;22:71-80.
23. Dieli F, Poccia F, Lipp M, et al. Differentiation of effector/memory Vδ2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 2003;198:391-7.
24. Wilhelm M, Kunzmann V, Eckstein S, et al. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 2003;102:200-6.
25. Dieli F, Gebbia N, Poccia F, et al. Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003;102:2310-1.
26. Kobayashi H, Tanaka Y, Yagi J, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using γδ T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007;56:469-76.
27. Cannon GM, Jr., Walsh PC, Partin AW, Pound CR. Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. Urology 2003;62:2-8.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
29. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003;21:1404-11.
30. Body JJ. Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 2006;14:408-18.
31. Vermijlen D, Ellis P, Langford C, et al. Distinct cytokine-driven responses of activated blood γδ T cells: insights into unconventional T cell pleiotropy. J Immunol 2007;178:4304-14.
32. Wesch D, Glatzel A, Kabelitz D. Differentiation of resting human peripheral blood γδ T cells toward Th1-or Th2-phenotype. Cell Immunol 2001;212:110-7.
33. Eberl M, Engel R, Beck E, Jomaa H. Differentiation of human γδ T cells towards distinct memory phenotypes. Cell Immunol 2002;218:1-6.
34. Caccamo N, Meraviglia S, Ferlazzo V, et al. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vγ9Vδ2 naive, memory and effector T cell subsets. Eur J Immunol 2005;35:1764-72.
35. Whittington R, Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993;46:446-514.
36. Weber JS, Yang JC, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. J Clin Oncol 1992;10:33-40.
37. Peest D, Leo R, Bloche S, et al. Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma. Br J Haematol 1995;89:328-37.
38. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-66.
39. Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 2006;84:87-98.
40. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11:77-84.
41. Bucur O, Ray S, Bucur MC, Almasan A. APO2 ligand/ tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci 2006;11:1549-68.
42. Tateishi K, Ohta M, Guleng B, et al. TRAIL-induced cell death cooperates with IFN-γ activation in the graft-versus-tumor effect against colon tumors. Int J Cancer 2006;118:2237-46.
43. Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006;12:214-9.
44. Chou AH, Tsai HF, Lin LL, Hsieh SL, Hsu PI, Hsu PN. Enhanced proliferation and increased IFN-γ production in T cells by signal transduced through TNF-related apoptosis inducing ligand. J Immunol 2001;167:1347-52.
45. Uno T, Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006;12:693-8.
46. Moris A, Rothenfusser S, Meuer E, Hangretinger R, Fisch P. Role of γδ T cells in tumor immunity and their control by NK receptors. Microbes Infect 1999;1:227-34.
47. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001;413:165-71.